Assignee: JCR Pharmaceuticals Co., Ltd.

Location: Hyogo, JP
No. of patents: 36

Number	Title	Issue Date
7166764	Noc2 knockout mouse Disclosed are a mouse homozygous or heterozygous for the defect of the Noc2 gene, and a tissue and a cell of the mouse. The Noc2 knockout mice, which exhibit stress-related insulin hyposecretion and accumulation of secretory granules of increased size and irregular ...	01/23/2007
7067265	Sodium ion-driven chloride/bi-carbonate exchanger The present invention discloses DNAs comprising nucleotide sequences set forth as SEQ ID NO:1 or NO:3 encoding Na+-driven Cl−/HCO3− exchanger, proteins comprising amino acid sequences set forth as SEQ ID NO:2 or NO:4, ...	06/27/2006
6956104	Protein Rim2 Provided is a protein used in the development of a therapeutic agent for neuron- or endocrine cell-related diseases, in which the transport system is involved. The protein has an amino acid sequence with one or more amino acids deleted, substituted, inserted or adde...	10/18/2005
6790949	Protein Rim2 Provided is a protein used in the development of a therapeutic agent for neuron- or endocrine cell-related diseases, in which the transport system is involved. The protein has an amino acid sequence with one or more amino acids deleted, substituted, inserted or adde...	09/14/2004
6727355	Pharmaceutical composition for treatment of Duchenne muscular dystrophy The invention provides an isolated and purified DNA set forth as SEQ ID NO:15 in the Sequence Listing and an antisense oligonucleotide complementary to the DNA. The DNA represents the splicing enhancer sequence (SES) in exon 45 of human dystrophin gene, and serves a...	04/27/2004
7402150	Injection device Disclosed is an injection device for properly dissolving pharmaceutical agents contained in a two-compartment syringe having slidable front and rear walls, and then performing portionwise multiple injections. The injection device comprises a front casing designed to...	07/22/2008
7235253	Powder containing physiologically active peptide A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to ...	06/26/2007
6673899	Sodium ion-driven chloride /bi-carbonate exchanger The present invention discloses DNAs comprising nucleotide sequences set forth as SEQ ID NO:1 or NO:3 encoding Na+ -driven Cl--/HCO3 -- exchanger, proteins comprising amino acid sequences set forth as SEQ ID NO:2 or NO:4, and their h...	01/06/2004
6653466	Pharmaceutical composition for treatment of duchenne muscular dystrophy A therapeutic pharmaceutical composition for patients of Duchenne muscular dystrophy with entire loss of exon 20 in dystrophin mature mRNA is provided. The composition comprise as an active principle an antisense oligonucleotide consisting of a 20 to 50-n...	11/25/2003
6653467	Medicament for treatment of Duchenne muscular dystrophy Antisense oligonucleotides comprising a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO:1 or NO:2 are disclosed. The antisense oligonucleotides are used for treatment of specific types of Duchenne muscular dystrophy which is attr...	11/25/2003
6548284	Membrane-bound metalloprotease and soluble secreted form thereof Disclosed are metalloprotease proteins or their salts usable for treatment or prophylaxis of conformational diseases and for providing a screening kit for selection of carcinostatics and anti-metastatic agents. The metalloprotease proteins have an amino a...	04/15/2003
6492167	Ubiquitous potassium-channel proteins and their genes The present invention provides novel ATP-sensitive potassium-channel proteins which are present ubiquitously in the living bodies of animals, and their genes....	12/10/2002
6284734	Inhibitors against prostate-specific antigen According to the present invention, there are provided inhibitors against prostate-specific antigen which comprise as a minimum unit a peptide consisting of Gly-Phe-Tyr-Lys-Lys-Lys-Gln-Ser-Arg, and such inhibitors can be expected to constitute a therapeut...	09/04/2001
6238915	Mutant human growth hormones and their uses In accordance with the present invention, there are provided mutant human growth hormone proteins which exhibit enhanced affinity for growth hormone but lowered hormone activity, base sequences encoding the same and their production processes as well as u...	05/29/2001
6194634	Apt-sensitive potassium channel gene-defective animals A Kir6.2 gene-defective, non-human mammal, a mouse in particular, its tissues and cells are provided, wherein the ATP-sensitive potassium channel Kir6.2 gene, one of the subunits of KATP channels essential for insulin secretion by pancreatic &#...	02/27/2001
6150331	Human growth hormone-containing aqueous pharmaceutical composition Provided is an aqueous pharmaceutical composition comprising human growth hormone wherein said human growth hormone is dissolved in a benzalkonium chloride-containing, slightly to weakly acidic solution buffered, most preferably, with maleate. The composi...	11/21/2000
6110688	Process for purifying Tamm-Horsfall glycoprotein or uromodulin their purified products and method for making the discrimination between both of them The present invention provides a process for purifying Tamm-Horsfall glycoprotein (THG) and uromodulin, which permits THG and uromodulin to be purified with enhanced efficiency by the simplified procedure, as well as a method for making the discrimination...	08/29/2000
5985924	Metastasis suppressory agents The present invention provides novel metastasis suppressory agents with a lowered degree of toxicity, comprising ursolic acid or its salt as an active ingredient, which can be administered to patients per os or through injection, thus enabling the patient...	11/16/1999
5948752	Suppressory agents against hypercoagulation According to the present invention, there are provided suppressory agents against hypercoagulation which comprise as an effective ingredient protein C inhibitor with a molecular weight of 54 to 57 kDa (DS-PAGE) being capable of suppressing function of the...	09/07/1999
5919692	Ubiquitous ATP-sensitive potassium-channel genes The present invention provides novel ATP-sensitive potassium-channel proteins which are present ubiquitously in the living bodies of animals, and their genes....	07/06/1999
5917027	Nucleic acids encoding potassium-channel proteins The present invention provides DNAs of hଲIR and mଲIR, which are novel ATP-sensitive potassium channels being present specifically in the pancreatic cells, and proteins encoded by such DNAs, wherein by utilizing them, it is possible to produce ...	06/29/1999
5847084	Process for obtaining platelet factor-4 The present invention, using a readily available sulfated chitin as an adsorbent, can permit platelet factor-4 to be recovered through specific adsorption from a solution containing the same factor, in by far increased yields as compared with the conventi...	12/08/1998
5753123	Method for purifying thrombomodulin The present invention permits human urinary thrombomodulin to be purified by a simple and practical procedure, while it enables even a starting material with a lowered content of thrombomodulin to be purified by greater purification rate than the one with...	05/19/1998
5547945	Remitting agent for nephrotic syndrome and hepatopathy symptoms A remitting agent for nephrotic syndrome and hepatopathy symptoms is provided that which comprises water-soluble polysaccharides having poly-D-galacturonic acid as an effective constituent; polysaccharides having the following characteristic properties wh...	08/20/1996
5504065	Agent for treating or preventing AIDS using human urine trypsin inhibitor Human urine trypsin inhibitor is provided as an agent for treating acquired immunodeficiency syndrome (AIDS), preventing the infection with AIDS or preventing the onset of AIDS after such infection. It can be administered intravenously for the treatment a...	04/02/1996
5403731	Process of producing modified superoxide dismutase A modified superoxide dismutase represented by the formula: ##STR1## (wherein R is as defined below; SOD is a residue of superoxide dismutase) is produced, in a shortened period of reaction with a high and constant modification ratio, by reacting a p...	04/04/1995
5371196	Process for producing secretory immunoglobulin A preparations Secretory immunoglobulin A preparations substantially not containing virus are produced by a process wherein secretory immunoglobulin A which might be contaminated with viruses is (1) heated about 60° C. for about 10 hours, or (2) subjected to the reacti...	12/06/1994
5296223	Subtilisin as an oral thrombolytic agent There are provided thrombolytic agents suited for oral administration. The agent comprises a proteolytic enzyme of subtilisin family, such as subtilisin BPN', subtilisin Carsberg, subtilisin amylosacchariticus, etc., produced by microorganisms belonging t...	03/22/1994
5283239	Inhibitor of herpesvirus absorption LEM which is an aqueous extract of a mycelial culture of Lentinus Edodes and has a sugar composition composed of arabinose, xylose, glucose, mannose, galasctose, fucose and rhamnose, as well as a fraction of LEM which corresponds to molecular weights of 1...	02/01/1994
5281577	Inhibitor of the proliferation of herpes viruses and inhibitor of the recurrence of affections caused by their latent infection An inhibitor of the proliferation of herpesviruses and of the recurrence of affections caused by their latent infection, which is an active material obtained by fractional purification of the aqueous extract from cultured Lentinus edodes mycelia....	01/25/1994
5240864	Method of assaying or analyzing subtypes of human leukocyte interferons or their antibodies, and antibodies to be used therefor Antiserum which can recognize all subtypes of human leukocyte interferon is prepared from the blood of an animal immunized with partially purified human leukocyte interferon obtained from a culture of human leukocyte stimulated with Sendai virus. The anti...	08/31/1993

PatentStorm

Celebrity Inventors

PatentStorm News

Assignee: JCR Pharmaceuticals Co., Ltd.